Amgen, Inc. (AMGN) Shares Sold by Merriman Wealth Management LLC

Share on StockTwits

Merriman Wealth Management LLC lowered its stake in Amgen, Inc. (NASDAQ:AMGN) by 99.1% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,194 shares of the medical research company’s stock after selling 130,086 shares during the quarter. Merriman Wealth Management LLC’s holdings in Amgen were worth $227,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently bought and sold shares of the stock. BKD Wealth Advisors LLC boosted its stake in shares of Amgen by 3.9% during the 4th quarter. BKD Wealth Advisors LLC now owns 4,032 shares of the medical research company’s stock valued at $785,000 after buying an additional 150 shares during the period. Comprehensive Portfolio Management LLC boosted its stake in shares of Amgen by 4.7% during the 4th quarter. Comprehensive Portfolio Management LLC now owns 3,622 shares of the medical research company’s stock valued at $705,000 after buying an additional 164 shares during the period. Community Bank & Trust Waco Texas boosted its stake in shares of Amgen by 2.2% during the 4th quarter. Community Bank & Trust Waco Texas now owns 5,243 shares of the medical research company’s stock valued at $1,021,000 after buying an additional 113 shares during the period. Davis R M Inc. boosted its stake in shares of Amgen by 6.5% during the 4th quarter. Davis R M Inc. now owns 6,647 shares of the medical research company’s stock valued at $1,294,000 after buying an additional 406 shares during the period. Finally, Lodestar Investment Counsel LLC IL boosted its stake in shares of Amgen by 5.1% during the 4th quarter. Lodestar Investment Counsel LLC IL now owns 107,417 shares of the medical research company’s stock valued at $20,911,000 after buying an additional 5,182 shares during the period. 77.31% of the stock is currently owned by hedge funds and other institutional investors.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $175.73, for a total value of $351,460.00. Following the transaction, the director now directly owns 15,092 shares in the company, valued at $2,652,117.16. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last 90 days, insiders sold 6,000 shares of company stock worth $1,115,580. Company insiders own 0.25% of the company’s stock.

AMGN has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Amgen from a “hold” rating to a “buy” rating and set a $217.00 target price on the stock in a report on Friday, April 12th. Cowen reiterated a “buy” rating and issued a $234.00 target price on shares of Amgen in a report on Tuesday, February 26th. Cantor Fitzgerald reiterated a “hold” rating and issued a $221.00 target price on shares of Amgen in a report on Monday, April 1st. Mizuho set a $208.00 target price on shares of Amgen and gave the stock a “buy” rating in a report on Friday, April 12th. Finally, BidaskClub downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 29th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $209.05.

Shares of Amgen stock opened at $171.28 on Monday. The company has a current ratio of 2.77, a quick ratio of 2.53 and a debt-to-equity ratio of 2.71. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $210.19. The stock has a market cap of $104.47 billion, a PE ratio of 11.89, a price-to-earnings-growth ratio of 2.26 and a beta of 1.15.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.11. The firm had revenue of $5.56 billion for the quarter, compared to analyst estimates of $5.55 billion. Amgen had a net margin of 34.00% and a return on equity of 71.02%. The company’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period in the previous year, the business earned $3.47 earnings per share. Research analysts forecast that Amgen, Inc. will post 13.94 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a $1.45 dividend. The ex-dividend date is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a yield of 3.39%. Amgen’s dividend payout ratio (DPR) is presently 40.28%.

WARNING: This news story was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4354024/amgen-inc-amgn-shares-sold-by-merriman-wealth-management-llc.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: Dividend

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Autoliv  PT Lowered to $62.00 at Buckingham Research
Autoliv PT Lowered to $62.00 at Buckingham Research
Shotspotter  Cut to “Market Perform” at Northland Securities
Shotspotter Cut to “Market Perform” at Northland Securities
Buckingham Research Increases Sonic Automotive  Price Target to $20.00
Buckingham Research Increases Sonic Automotive Price Target to $20.00
Vail Resorts  Earns Market Perform Rating from Analysts at Wells Fargo & Co
Vail Resorts Earns Market Perform Rating from Analysts at Wells Fargo & Co
Johnson Outdoors  Downgraded by Sidoti
Johnson Outdoors Downgraded by Sidoti
Autoliv  Stock Rating Upgraded by Robert W. Baird
Autoliv Stock Rating Upgraded by Robert W. Baird


© 2006-2019 Ticker Report